Drug counterfeiting is the crime of the 21st century, says Ron Guido, and to fight it, the pharmaceutical industry must work together. Guido is hopeful that industry groups such as Rx-360 and efforts to develop federal legislation like the Safeguarding America's Pharmaceuticals Act of 2013 and supporting regulations will make a difference, but there is much work left undone.
Today’s pharmaceuticals are increasingly being delivered via novel routes, and many are designed for patients to use when treating themselves. “Drug products are undergoing design revisions, giving changing patient populations user-friendly options,” explains Don Singer, Global Lead Quality Manager, Microbiology R&D, GlaxoSmithKline. “It is not just pills and tablets any more. We are seeing many inhalable and intranasal products, and parenterals are no longer just delivered directly by standard syringes and from vials, especially in the oncology field.